[1] S.D DONEVAN M. A R. Allosteric regulation of α-amino-3-hydroxy-5-methyl-4-isoxazole-propionate receptors by thiocyanate and cyclothiazide at a common modulatory site distinct from that of 2,3-benzodiazepines[J]. Neuroscience, 1998, 87 3: Pages 615-629. DOI:
10.1016/s0306-4522(98)00109-2[2] M A DESAI. Cyclothiazide acts at a site on the alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid receptor complex that does not recognize competitive or noncompetitive AMPA receptor antagonists.[J]. Journal of Pharmacology and Experimental Therapeutics, 1995, 272 1: 38-43.
[3] XAVIER JEUNEMAITRE MD. Long-term metabolic effects of spironolactone and thiazides combined with potassium-sparing agents for treatment of essential hypertension[J]. American Journal of Cardiology, 1988, 62 16: Pages 1072-1077. DOI:
10.1016/0002-9149(88)90551-6[4] JINSHUN QI. Cyclothiazide induces robust epileptiform activity in rat hippocampal neurons both in vitro and in vivo[J]. Journal of Physiology-London, 2006, 571 3: 605-618. DOI:
10.1113/jphysiol.2005.103812[5] SHUZHEN KONG . Cyclothiazide induces seizure behavior in freely moving rats[J]. Brain Research, 2010, 1355: Pages 207-213. DOI:
10.1016/j.brainres.2010.07.088